See more : Star Cement Limited (STARCEMENT.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Syngen Biotech Co.,Ltd. (8279.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syngen Biotech Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Samsung Electronics Co., Ltd. (005935.KS) Income Statement Analysis – Financial Results
- Global Net Lease, Inc. (GNL-PB) Income Statement Analysis – Financial Results
- Costa Group Holdings Limited (CGC.AX) Income Statement Analysis – Financial Results
- Nureca Limited (NURECA.NS) Income Statement Analysis – Financial Results
- Diagonal Bio AB (publ) (DIABIO.ST) Income Statement Analysis – Financial Results
Syngen Biotech Co.,Ltd. (8279.TWO)
About Syngen Biotech Co.,Ltd.
Syngen Biotech Co.,Ltd. engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicine. It also offers contract manufacturing; science-based and bio active pharmaceutical ingredients; and private labelling. In addition, the company provides organic food OEM/ODM, explosion proof extraction, brand agency, and wholesale distribution services. The company was founded in 1988 and is based in Tainan City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.84B | 1.93B | 1.47B | 1.31B | 1.30B |
| Cost of Revenue | 1.19B | 1.24B | 942.93M | 816.02M | 829.34M |
| Gross Profit | 643.92M | 688.15M | 528.34M | 495.41M | 467.93M |
| Gross Profit Ratio | 35.05% | 35.64% | 35.91% | 37.78% | 36.07% |
| Research & Development | 46.76M | 45.32M | 49.52M | 43.42M | 52.95M |
| General & Administrative | 134.90M | 100.69M | 74.67M | 76.02M | 0.00 |
| Selling & Marketing | 167.99M | 161.94M | 122.35M | 118.48M | 0.00 |
| SG&A | 302.88M | 262.63M | 197.02M | 194.51M | 172.09M |
| Other Expenses | 0.00 | 11.86M | 2.10M | 4.34M | 0.00 |
| Operating Expenses | 341.06M | 307.96M | 246.54M | 237.92M | 225.03M |
| Cost & Expenses | 1.53B | 1.55B | 1.19B | 1.05B | 1.05B |
| Interest Income | 1.43M | 609.00K | 319.00K | 2.24M | 300.00K |
| Interest Expense | 8.86M | 5.07M | 3.21M | 2.47M | 3.65M |
| Depreciation & Amortization | 99.47M | 86.50M | 81.40M | 76.67M | 64.21M |
| EBITDA | 442.14M | 505.81M | 380.42M | 340.73M | 308.11M |
| EBITDA Ratio | 24.07% | 26.20% | 25.86% | 25.98% | 23.75% |
| Operating Income | 294.28M | 419.31M | 299.03M | 264.07M | 242.90M |
| Operating Income Ratio | 16.02% | 21.72% | 20.32% | 20.14% | 18.72% |
| Total Other Income/Expenses | 39.52M | -22.89M | -3.53M | -692.00K | -2.64M |
| Income Before Tax | 333.80M | 396.42M | 295.49M | 263.38M | 240.26M |
| Income Before Tax Ratio | 18.17% | 20.53% | 20.08% | 20.08% | 18.52% |
| Income Tax Expense | 58.98M | 75.18M | 57.72M | 47.83M | 51.49M |
| Net Income | 274.83M | 321.24M | 237.77M | 215.55M | 188.77M |
| Net Income Ratio | 14.96% | 16.64% | 16.16% | 16.44% | 14.55% |
| EPS | 10.14 | 11.85 | 8.77 | 7.95 | 7.86 |
| EPS Diluted | 10.13 | 11.84 | 8.76 | 7.94 | 7.85 |
| Weighted Avg Shares Out | 27.10M | 27.10M | 27.10M | 27.10M | 24.02M |
| Weighted Avg Shares Out (Dil) | 27.13M | 27.13M | 27.13M | 27.13M | 24.05M |
Source: https://incomestatements.info
Category: Stock Reports